Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Pericardial Histopathology and COVID-19 Seropositivity

  • Read more about Pericardial Histopathology and COVID-19 Seropositivity

Feasibility and Preliminary Efficacy of a Group-based Telerehabilitation Program in People With Post-COVID-19 Sequelae (TEPCO).

  • Read more about Feasibility and Preliminary Efficacy of a Group-based Telerehabilitation Program in People With Post-COVID-19 Sequelae (TEPCO).

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

  • Read more about Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC

  • Read more about Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC

GemVax & KAEL Co. Ltd.

By jpalfreyman on Fri, 04/25/2025 - 09:34
  • Read more about GemVax & KAEL Co. Ltd.

Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation

  • Read more about Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation

Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Post COVID-19

  • Read more about Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Post COVID-19

Coronavirus Disease of 2019 (COVID-19) Health Education Initiative for School Safety

  • Read more about Coronavirus Disease of 2019 (COVID-19) Health Education Initiative for School Safety

Frontier Medicines Corporation

By jpalfreyman on Tue, 04/22/2025 - 14:19
  • Read more about Frontier Medicines Corporation

Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC

  • Read more about Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Current page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA